Compare LSPD & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | AAPG |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | 2024 |
| Metric | LSPD | AAPG |
|---|---|---|
| Price | $10.20 | $15.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 11 |
| Target Price | $10.90 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 715.0K | 5.4K |
| Earning Date | 11-05-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.74 | $17.92 |
| Revenue Next Year | $11.32 | $111.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.83 | $13.46 |
| 52 Week High | $12.69 | $34.50 |
| Indicator | LSPD | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 46.93 |
| Support Level | $9.93 | $14.50 |
| Resistance Level | $11.05 | $16.41 |
| Average True Range (ATR) | 0.36 | 0.46 |
| MACD | -0.13 | 0.07 |
| Stochastic Oscillator | 21.93 | 55.14 |
Lightspeed Commerce Inc is a one-stop commerce platform providing its customers with the critical functionalities needed to engage with consumers, manage their operations, order their inventory, accept payments, and run their business. It has customers globally in over 100 countries, empowering single- and multi-location small and medium-sized businesses to compete in an omni-channel market environment by engaging with consumers across online, mobile, social, and physical channels. Its products are divided into retail, restaurant, and golf categories. Geographically, it operates in Canada, the United States, the United Kingdom, Switzerland, Germany, and Others with the majority of revenue deriving from Canada.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.